Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 20Unknown 16Terminated 3Active not recruiting 3Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Thyroid Nodule 2Breast Neoplasms 2Thyroid Neoplasms 1Recurrence 1Pancreatic Neuroendocrine Tumors, WHO Grade I-II 1Neuroma 1Neuralgia 1Lymphoma, Follicular 1Liver Metastasis Colon Cancer 1Lipoma 1Klatskin Tumor 1Kidney Neoplasms 1Hypesthesia 1Esophageal Neoplasms 1Cicatrix 1Carcinoma, Hepatocellular 1Bone Cancer Metastatic 1Bile Duct Neoplasms 1Agnosia 1Adrenocortical Adenoma 1Adenoma, Islet Cell 1

Interventions

Bevacizumab 48lenvatinib 36atezolizumab 36durvalumab 28tremelimumab 23sintilimab 19Nivolumab 18pembrolizumab 14Radiosurgery 13tislelizumab 11Specimen Handling 10Ipilimumab 10camrelizumab 9apatinib 9Oxaliplatin 8Immune Checkpoint Inhibitors 8Fluorouracil 8Cyclophosphamide 8regorafenib 7cabozantinib 7Magnetic Resonance Spectroscopy 7Blood Specimen Collection 7fludarabine 6Sorafenib 6Radiotherapy 6Leucovorin 6donafenib 5Surgical Procedures, Operative 5Injections 5Immunoglobulin G 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Hepatocellular × Radiofrequency Ablation × Clear all
NCT04150744 2020-07-08

RFA Plus Carrizumab vs Carrizumab Alone for HCC

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Recruiting
120 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡